UY40047A - Inhibidores de apol1 y métodos de uso de estos - Google Patents

Inhibidores de apol1 y métodos de uso de estos

Info

Publication number
UY40047A
UY40047A UY0001040047A UY40047A UY40047A UY 40047 A UY40047 A UY 40047A UY 0001040047 A UY0001040047 A UY 0001040047A UY 40047 A UY40047 A UY 40047A UY 40047 A UY40047 A UY 40047A
Authority
UY
Uruguay
Prior art keywords
apol1
methods
tautomers
pharmaceutically acceptable
inhibitors
Prior art date
Application number
UY0001040047A
Other languages
English (en)
Spanish (es)
Inventor
A Dakin Leslie
J Senter Timothy
A Brodney Michael
B Daniel Kevin
Elena Dolgikh
M Garcia Barrantes Pedro
Ales Medek
H Olsen Jessica
J Shimizu Akira
D Stone Steven
Charlene Tsay
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of UY40047A publication Critical patent/UY40047A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001040047A 2021-11-30 2022-11-30 Inhibidores de apol1 y métodos de uso de estos UY40047A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284166P 2021-11-30 2021-11-30
US202163286165P 2021-12-06 2021-12-06
US202263310832P 2022-02-16 2022-02-16

Publications (1)

Publication Number Publication Date
UY40047A true UY40047A (es) 2023-06-15

Family

ID=84981152

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040047A UY40047A (es) 2021-11-30 2022-11-30 Inhibidores de apol1 y métodos de uso de estos

Country Status (19)

Country Link
US (1) US12612379B2 (https=)
EP (1) EP4441032A1 (https=)
JP (1) JP2024543934A (https=)
KR (1) KR20240131345A (https=)
AU (1) AU2022402839A1 (https=)
CA (1) CA3239394A1 (https=)
CL (1) CL2024001586A1 (https=)
CO (1) CO2024006736A2 (https=)
CR (1) CR20240261A (https=)
DO (1) DOP2024000104A (https=)
EC (1) ECSP24050151A (https=)
GE (1) GEAP202416543A (https=)
IL (1) IL312747A (https=)
JO (1) JOP20240120A1 (https=)
MX (1) MX2024006473A (https=)
PE (1) PE20241628A1 (https=)
TW (1) TW202329951A (https=)
UY (1) UY40047A (https=)
WO (1) WO2023102022A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
FR2793246B1 (fr) 1999-05-03 2001-06-29 Adir Nouveaux derives de 1-aza-2-alkyl-6-aryl-cycloalcanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
JP2007504221A (ja) 2003-09-03 2007-03-01 ガラパゴス・エヌブイ 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
JP5406722B2 (ja) 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
CN106749330A (zh) 2016-12-29 2017-05-31 长春海谱润斯科技有限公司 一种杂环衍生物及使用该杂环衍生物的有机发光器件
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
IL296423A (en) 2020-04-22 2022-11-01 Anima Biotech Inc Collagen 1 translation inhibitors and methods of use thereof
JP2023524563A (ja) 2020-05-07 2023-06-12 ラムバム メド－テック リミテッド Ａｐｏｌ１－関連疾患の治療に使用するための組成物
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
EP4440697A1 (en) 2021-11-30 2024-10-09 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
CN119212986A (zh) 2022-02-08 2024-12-27 弗特克斯药品有限公司 作为apol1的抑制剂的螺哌啶衍生物及其使用方法
AU2023219516A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
CA3251050A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
MX2024006473A (es) 2024-06-19
CR20240261A (es) 2024-07-29
US12612379B2 (en) 2026-04-28
IL312747A (en) 2024-07-01
US20230203000A1 (en) 2023-06-29
AU2022402839A1 (en) 2024-05-30
CO2024006736A2 (es) 2024-07-18
GEAP202416543A (en) 2024-10-10
WO2023102022A1 (en) 2023-06-08
CL2024001586A1 (es) 2024-10-18
PE20241628A1 (es) 2024-08-07
KR20240131345A (ko) 2024-08-30
ECSP24050151A (es) 2024-07-31
DOP2024000104A (es) 2024-07-15
JOP20240120A1 (ar) 2024-05-28
EP4441032A1 (en) 2024-10-09
CA3239394A1 (en) 2023-06-08
TW202329951A (zh) 2023-08-01
JP2024543934A (ja) 2024-11-26

Similar Documents

Publication Publication Date Title
UY40047A (es) Inhibidores de apol1 y métodos de uso de estos
CO2023003026A2 (es) Inhibidores de apol1 y métodos para usar los mismos
CO2024012060A2 (es) Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos
CO2024012058A2 (es) Derivados de 2-metil-4’,5’-dihidrospiro[piperidina-4,7’-tieno[2,3-c]pirano] como inhibidores de apol1 y métodos de uso de los mismos
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
MX2021007152A (es) Inhibidores de apol1 y sus metodos de uso.
RU2342367C2 (ru) Ненуклеозидные ингибиторы i обратной транскриптазы, предназначенные для лечения заболеваний, опосредованных вич
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
MX2021015319A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.
BR112017020131A2 (pt) derivados de 7-(morfolin-4-il)pirazol[1,5-a]pirimidina que são úteis para o tratamento de doenças imunológicas ou inflamatórias ou câncer
BR112022005706A2 (pt) Inibidores de 1,6-naftiridina substituída de cdk5
UY27132A1 (es) Naftostirilos
EA200500072A1 (ru) Новые фторированные соединения бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
AR027255A1 (es) Compuestos de imidazol
AR134197A1 (es) Compuestos para el tratamiento de enfermedad renal
ES2653674B2 (es) Aminas derivadas de 5- Nitroindazol con propiedades antiprotozoarias
AR134697A1 (es) Compuestos químicos y sus usos